Back to Agenda
Feasible Site Feasibility Assessments: Rethinking Business as Usual to Reduce Burden, Timelines, and Costs for Sustainability
Session Chair(s)
Trevor Joseph Cole, MBA, RN, PMP
Associate Director
WCG, United States
In 2021, recommendations to reduce site feasibility assessment burdens was released.. Current industry and CRO methods remain costly and inefficient, and delay trial start-up and patient access to clinical trials.
Learning Objective : Describe the impact of non-standardized study feasibility assessments across the industry; Discuss opportunities and solutions around improvements to the site feasibility assessment process; Apply new methods to streamline feasibility assessments and improve study start-up timelines.
Speaker(s)
Panelist
Kristen Ballesteros, PhD, MS
Thermo Fischer Scientific, PPD, United States
Associate Director, Feasibility Strategy
Panelist
Suanna S. Bruinooge, MPH
American Society of Clinical Oncology, United States
Chief and Division Director, Research Strategy and Operations Center
Panelist
Ramya Thota
Intermountain Medical Oncology - IMC, United States
Associate Professor
Have an account?